J&J Quits RSV Development With Two Rivals Already Poised For US Approval

29 Mar 2023

The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.

J&J steps away from RSV vaccine development • Source: Michael Vi / Shutterstock.com

Johnson & Johnson revealed on 29 March that it is ending development of its respiratory syncytial virus (RSV) vaccine candidate, effectively shuttering its 20,000-plus patient Phase III study mid-stream, due to the fact that competitors appear likely to beat them to the market. GSK plc and Pfizer Inc. have RSV candidates filed for approval at the US Food and Drug Administration with action dates in May. J&J said enrollment was ongoing at the time of its decision.

J&J was roughly a year behind its two peers in terms of reporting data from the pivotal EVERGREEN study. Its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

25 Jul 2025

• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

24 Jul 2025

• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.